Show simple item record

dc.contributor.authorSkuli, Sarah J
dc.contributor.authorAlomari, Safwan
dc.contributor.authorGaitsch, Hallie
dc.contributor.authorBakayoko, A'ishah
dc.contributor.authorSkuli, Nicolas
dc.contributor.authorTyler, Betty M
dc.date.accessioned2022-06-29T19:47:38Z
dc.date.available2022-06-29T19:47:38Z
dc.date.issued2022-05-19
dc.identifier.citationPharmaceuticals (Basel, Switzerland), volume 15, issue 5, page 626
dc.identifier.issn1424-8247
dc.identifier.other35631452
dc.identifier.otherPMC9144507
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/338545
dc.description.abstractThe deregulation of energetic and cellular metabolism is a signature of cancer cells. Thus, drugs targeting cancer cell metabolism may have promising therapeutic potential. Previous reports demonstrate that the widely used normoglycemic agent, metformin, can decrease the risk of cancer in type 2 diabetics and inhibit cell growth in various cancers, including pancreatic, colon, prostate, ovarian, and breast cancer. While metformin is a known adenosine monophosphate-activated protein kinase (AMPK) agonist and an inhibitor of the electron transport chain complex I, its mechanism of action in cancer cells as well as its effect on cancer metabolism is not clearly established. In this review, we will give an update on the role of metformin as an antitumoral agent and detail relevant evidence on the potential use and mechanisms of action of metformin in cancer. Analyzing antitumoral, signaling, and metabolic impacts of metformin on cancer cells may provide promising new therapeutic strategies in oncology.
dc.languageeng
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceessn: 1424-8247
dc.sourcenlmid: 101238453
dc.subjectDiabetes
dc.subjectTherapeutics
dc.subjectMetformin
dc.subjectPI3K
dc.subjectAmpk
dc.subjectCancer Metabolism
dc.subjectDrug Repurposing
dc.titleMetformin and Cancer, an Ambiguanidous Relationship.
dc.typeArticle
dc.date.updated2022-06-29T19:47:38Z
prism.publicationNamePharmaceuticals (Basel)
dc.identifier.doi10.17863/CAM.85958
dcterms.dateAccepted2022-05-12
rioxxterms.versionofrecord10.3390/ph15050626
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidAlomari, Safwan [0000-0002-7595-818X]
dc.contributor.orcidGaitsch, Hallie [0000-0002-6656-607X]
dc.contributor.orcidTyler, Betty M [0000-0001-9800-6969]
dc.identifier.eissn1424-8247
cam.issuedOnline2022-05-19


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International